LLMpediaThe first transparent, open encyclopedia generated by LLMs

Protein Structure Initiative

Generated by GPT-5-mini
Note: This article was automatically generated by a large language model (LLM) from purely parametric knowledge (no retrieval). It may contain inaccuracies or hallucinations. This encyclopedia is part of a research project currently under review.
Article Genealogy
Expansion Funnel Raw 43 → Dedup 0 → NER 0 → Enqueued 0
1. Extracted43
2. After dedup0 (None)
3. After NER0 ()
4. Enqueued0 ()
Protein Structure Initiative
NameProtein Structure Initiative
Established2000
Dissolved2015
TypeResearch program
HeadquartersUnited States
Parent organizationNational Institutes of Health; National Institute of General Medical Sciences

Protein Structure Initiative

The Protein Structure Initiative was a large-scale biomedical research program launched to accelerate determination of three-dimensional structures of proteins and to develop methods for rapid structure elucidation. It linked high-throughput structural biology centers, academic laboratories, and computational resources to address bottlenecks in structure determination and to enable discovery across structural biology, biochemistry, and molecular biology. The initiative influenced policy-making at National Institutes of Health and fostered partnerships among institutions such as University of California, San Diego, University of Wisconsin–Madison, and national laboratories.

Overview

The program organized consortia of structural biologists, crystallographers, NMR spectroscopists, and computational scientists to produce thousands of protein structures for databases like the Protein Data Bank and to develop pipelines for target selection, cloning, expression, purification, and structure determination. It integrated technologies from synchrotron facilities such as Argonne National Laboratory and Brookhaven National Laboratory with informatics groups at centers including The Scripps Research Institute and Lawrence Berkeley National Laboratory. Funding, policy, and oversight involved agencies and advisory bodies including the National Institute of General Medical Sciences and panels drawn from the National Academy of Sciences.

History and organization

The initiative began in 2000 under program announcements from National Institutes of Health and expanded through phases overseen by program officers and steering committees with representation from universities and national labs. Early organizational models included large-scale Production Centers, Specialized Centers, and Technology Development groups affiliated with institutions like University of California, San Diego, University of Wisconsin–Madison, Northwestern University, and the University of Chicago. Governance incorporated interactions with community stakeholders such as the American Society for Biochemistry and Molecular Biology and reporting mechanisms to congressional oversight committees and scientific review panels convened by National Institutes of Health.

Goals and scientific contributions

Primary goals emphasized high-throughput determination of novel folds, development of reagents for structural studies, and creation of software and databases to support modeling efforts used by investigators affiliated with centers such as Scripps Research, Dana-Farber Cancer Institute, and Cold Spring Harbor Laboratory. Scientific contributions included depositions to the Protein Data Bank that expanded fold-space coverage, improvements in homology modeling exploited by groups at Harvard University and Massachusetts Institute of Technology, and resources for functional annotation used by teams at Johns Hopkins University and Stanford University. The initiative supported training and technology transfer to academic cores at institutions like University of Texas Southwestern Medical Center and University of California, San Francisco.

Methods and technologies

The program catalyzed automation in cloning and expression systems drawing on platforms developed at Lawrence Livermore National Laboratory and robotic crystallization pipelines linked to beamlines at Advanced Photon Source and NSLS-II facilities. It promoted advances in X-ray crystallography, nuclear magnetic resonance through collaborations with groups at University of Michigan, and emerging cryo-electron microscopy approaches informed by centers including National Center for CryoEM Access and Training and Janelia Research Campus. Computational developments included automated model building and validation tools integrated into workflows at European Bioinformatics Institute-partner labs and software contributions used by researchers at University of California, Berkeley and University of Washington.

Major centers and collaborations

Major Production Centers and Specialized Centers were hosted by institutions such as University of California, San Diego, University of Wisconsin–Madison, Northwestern University, Stanford University School of Medicine, The Scripps Research Institute, and Rutgers University. Collaborative networks extended to national facilities like Argonne National Laboratory, Brookhaven National Laboratory, and international partners including groups at European Molecular Biology Laboratory, Max Planck Institute for Biochemistry, and University of Cambridge. Interdisciplinary training and resource sharing connected researchers from Yale University, Princeton University, Columbia University, and medical centers such as Mayo Clinic.

Impact and legacy

The enterprise reshaped expectations for throughput in structural biology, influenced funding strategies at National Institutes of Health and National Institute of General Medical Sciences, and seeded technology and software now standard in cores at universities like University of California, San Francisco and Johns Hopkins University. Data and methods from the program accelerated structural annotation efforts used by bioinformatics groups at European Bioinformatics Institute, structural modeling at University of California, Berkeley, and drug discovery projects at pharmaceutical partners including Pfizer and Merck & Co.. Although the program transitioned to investigator-driven research, its legacy persists in community resources, automated pipelines, and a cadre of structural scientists trained at centers such as University of Wisconsin–Madison and Scripps Research.

Category:Biological research programs